# MACROPHAGE AGGLUTINATION FACTOR

> **NIH NIH R01** · NEW YORK MEDICAL COLLEGE · 1989 · $163,347

## Abstract

Alterations in cellular immunity and in production of lymphokines
(non-immunoglobulin mediators of immune responses) occur in
patients with diseases ranging from cancer to occupationally-
acquired allergic contact dermatitis.  Clarification of the in vivo
role of lymphokines and accurate quantification of them in vitro
depends on biochemical characterization and production of
specific antibodies as reagents for further analysis of these
molecules.  Macrophage agglutination factor (MAggF) is a
fibronectin (FN)-related lymphokine associated with cell-
mediated inflammatory reactions in guinea pigs, mice and human
beings.  The FNs are a family of closely related high molecular
weight glycoproteins involved in cell adhesion and regulation of
cell morphology with binding sites for collagen, heparin, fibrin and
cells.  Subproject 1 will continue further characterization of
MAggF with the aim of clarifying the relationship of MAggF and
FN.  The specificity and activity of monoclonal anti-MAggF and
anti-FN antibodies will be characterized in order to discover
antibodies specific for MAggF and not cross reactive with other
FNs.  Biochemical and immunochemical properties of MAggF
purified by gelatin affinity chromatography and immunoabsorption
will be compared to those of plasma FN.  In subproject 2,
characterized anti-MAggF and anti-FN antibodies will be used to
evaluate the role of MAggF in vivo in contact dermatitis and
delayed hypersensitivity reactions, and in vitro in an antigen-bead
model of cell-mediated inflammation.  Subproject 3 will focus on
the effects of MAggF on macrophages and the mechanisms of
these effects.  The role of macrophage complement receptors in
the response to MAggF will be examined as will the ability of
purified MAggF to effect changes in macrophage phagocytosis and
production of arachidonic acid metabolites.  The effects of
eicosanoids and other adherence factors in modifying response to
MAggF will also be investigated.  Subproject 4 will study
regulation of MAggF production by thymic hormones,
macrophages, and macrophage products such as alpha2
macroglobulin and eicosanoids.  In this and other subprojects,
MAggF will be quantitated by bioassay and by immunoassay based
on anti-FN and anti-MAggF antibodies.  In subproject 4 in
particular, these antibodies will be used to isolate metabolically
labeled MAggF to provide direct evidence for mechanism(s)
regulating MAggF production by T cells.

## Key facts

- **NIH application ID:** 3171900
- **Project number:** 5R01CA034141-08
- **Recipient organization:** NEW YORK MEDICAL COLLEGE
- **SAM.gov UEI:** WK63UJ11C2H7
- **Principal Investigator:** HENRY Philip GODFREY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $163,347
- **Award type:** 5
- **Project period:** 1982-07-01 → 1992-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171900

## Citation

> US National Institutes of Health, RePORTER application 3171900, MACROPHAGE AGGLUTINATION FACTOR (5R01CA034141-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171900. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*